Protease nexin-1 (PN-1) is a serpin which inhibits plasminogen activators, plasmin and thrombin. PN-1 is barely detectable in plasma, but is expressed by platelets. Here, we studied platelet PN-1 in resting and activated conditions and its function in thrombosis. Studies on human platelets from healthy donors and from patients with a Gray platelet syndrome demonstrate that PN-1 is present both at the platelet surface and in alpha-granules. The role of PN-1 was investigated in vitro using human platelets incubated with a blocking antibody, and using platelets from PN-1-deficient mice. Both approaches indicate that platelet PN-1 is active on thrombin and urokinase-type plasminogen activator (uPA). Blockade and deficiency of platelet PN-1 result in accelerated and increased tissue factor-induced thrombin generation as indicated by calibrated automated thrombography. Moreover, platelets from PN-1-deficient mice respond to sub-threshold doses of thrombin, as assessed by P-selectin expression and platelet aggregation. Thrombus formation, induced ex vivo by collagen in blood flow conditions and in vivo by FeCl 3 -induced injury, is significantly increased in PN-1-deficient mice, demonstrating the antithrombotic properties of platelet PN-1. Platelet PN-1 is thus a key player in the thrombotic process, whose negative regulatory role has been, up to now, markedly underestimated.
Introduction
time, by in vitro studies on platelet activation and thrombin generation, ex vivo studies on thrombus formation in blood flow conditions, and in vivo studies using a model of arteriolar and venular thrombosis in mice, that platelet PN-1 has relevant anticoagulant and antithrombotic properties. Platelet PN-1 is thus a key player in the thrombotic process whose negative regulatory role has been, up to now, markedly underestimated.
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Materials and methods

Patients
The three patients are from unrelated families and present hemorrhagic manifestations related to a well characterized GPS. One case has already been reported in the literature 15 and two are new sporadic cases. All patients gave informed consent in accordance with the Declaration of Helsinki.
Animals
Mice homozygous for null mutations in the PN-1 or PAI-1 gene were generated, as previously described. 16, 17 Experimental animals were 8-16 weeks of age. PN-1-deficient mice (PN-1 -/-) were back-crossed for 12 generations into the C57BL/6 line. Heterozygous mating generated PN-1 -/-and wild-type mice (WT). Mice were bred and maintained in our own laboratory (Paris, France). PAI-1-deficient mice (PAI-1 -/-) come from HR Lijnen Laboratory (Leuven, Belgium). All animals were genotyped by PCR. All experiments were performed in accordance with European legislation on the protection of animals and were approved by the ethics committee of INSERM.
Preparation of washed platelets
Human platelets
Human blood from healthy adult volunteers was collected into 1/10 vol. ACD-A (38 mM citric acid, 60 mM sodium citrate, 136 mM glucose). Washed platelets were isolated as previously described.
18
Mouse platelets
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Urokinase (uPA) activity assay
Secreted fractions were obtained human and mouse platelets as described above and incubated with 1 nM uPA (American Diagnostica, France) for 30 min at 37°C in the presence or absence of the blocking anti-PN-1 or anti-PAI-1 IgGs. At the end of the incubation, the urokinase-specific chromogenic substrate S2444 (Chromogenix, France) was added at a final concentration of 1 mM and changes in the absorbance recorded at 405 nm. Residual uPA activity is expressed as the ratio of the activity measured in the presence of the fraction secreted by activated platelets to the activity measured in the presence of the supernatant of resting platelets × 100.
Thrombin generation in human and mouse PRP
Thrombin generation was continuously measured in PRP using the thrombogram method as previously described. 26 Human PRP (1.5×10 8 platelets/mL) was pre-incubated with the blocking anti-PN-1 or anti-PAI-1 IgGs (150 µg/mL) for 15 min at 37°C. Then PRP was transferred to microtitration plates containing 0.5 pM tissue factor (TF) (Diagnostica Stago, France). For measurements on mouse PRP, platelets were adjusted to 1×10 8 /mL and thrombin generation was initiated by 1 pM TF as previously described.
27
Collagen-induced thrombus formation under flow conditions.
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Citrate-anticoagulated murine blood was labelled by Rhodamine 6G (Sigma, France) and perfused at a shear rate of 1000s -1 over a collagen surface, as described elsewhere 28 (a detailed protocol is given in supplemental methods).
In vivo thrombosis
Ferric chloride injury was induced in four to five week-old mice as previously described 29 (a detailed protocol is given in supplemental methods).
Statistics
Results are shown as means plus or minus SD. Statistical analysis of differences between groups was performed using a Student's t-test. A value of P≤ 0.05 was considered as significant.
Results
PN-1 is expressed by human platelets and is secreted during activation
To investigate whether platelet PN-1 is an endogenous protein or results from the uptake of extracellular PN-1 by platelets, platelet mRNAs were analyzed by RT-PCR. The PN-1 amplification product detected ( Figure 1A ) and the fact that PN-1 is not present in the plasma, strongly suggested an endogenous origin. PN-1 expression by platelets was analyzed by immunoblot on human washed platelets ( Figure 1B ). PN-1 was detected as a 50 kDa band in extracts of resting platelets, migrating slightly faster than recombinant PN-1 (rPN-1) due to differences in glycosylation, as previously reported. 30 Platelet activation was induced by different agonists. After centrifugation, immunoblots were performed on platelet extracts obtained from pellets and on secretion products obtained from the supernatants. PN-1 was no longer detected in the platelet extracts following activation by 5 nM thrombin, 50 µM PAR1-AP, 5 µg/mL collagen or 1 nM convulxin ( Figure 1B) . In contrast, a 50 kDa band corresponding to intact PN-1 was detected in the secretion products of activated platelets ( Figure 1B ), indicating that PN-1 was secreted during platelet activation by strong agonists.
After activation by 10 µM ADP, a weak agonist, or when platelets were incubated with PGE 1 , a cAMP-increasing agent which inhibits platelet activation, before activation by thrombin, PN-1 was still detected in platelet extracts and barely detectable in the secretion products ( Figure 1B-C) . These data indicate that platelet PN-1 is secreted by an activation-dependent mechanism.
PN-1 is bound to glycosaminoglycans at the platelet surface
To determine whether PN-1 was present on the platelet surface, flow cytometry analysis was performed using a FITC-coupled anti-PN-1 monoclonal antibody. A single population of labelled platelets was observed, indicating the presence of PN-1 at the surface of platelets ( Figure 1D ). Platelets analyzed were resting platelets as indicated by the absence of significant labelling with the anti-P-selectin IgG (<1% positive platelets). After activation by PAR1-AP, fluorescence peak shifted to the left indicating a decrease in the expression of PN-1 at the surface of activated platelets. (Figure 1D ).
Plasma membrane and cytosol fractions of resting platelets were analyzed by immunoblot. PN-1 was detected in the cytosol and the membrane fractions of resting platelets. However, the intensity of the band in the membrane fraction was considerably less intense than the one in the cytosol fraction, indicating that membrane-bound PN-1 represents a minor part of platelet PN-1 ( Figure 1E ).
PN-1 is known to bind to cell surface GAGs from which it is detached by heparin. 31 Flow cytometry analysis of resting platelets showed that heparin induced a significant shift to the left of the platelet-associated fluorescence, indicating a decrease in PN-1 at the platelet surface ( Figure 1F ). In addition, an increased amount of PN-1 was detected by immunoblot analysis in the incubation medium ( Figure 1F , insert). These results indicate that the fraction of platelet PN-1 present at the platelet surface is mainly associated with membrane-bound GAGs.
PN-1 is stored in platelet α
-granules
The results reported above suggested that the major part of platelet PN-1 was stored in secretory granules. Platelets from three patients with a GPS, a rare platelet disorder characterized by thrombocytopenia with an absence of α -granules, 32 were investigated.
Washed platelets from healthy donors or GPS patients (5×10 Figure 3A ). These results suggested that PN-1 was the major inhibitor of thrombin activity released by activated platelets, and that platelet-derived PAI-1 was inefficient on thrombin activity. The effect of the secretion products obtained after activation of GPS-platelets was thus analyzed on thrombin activity. In these conditions, no inhibition of thrombin activity was observed ( Figure 3B ). Taken together, these data strongly suggest, on one hand, that PN-1 is stored in α -granules and, on the other hand, that PN-1 is the main thrombin inhibitor released by activated platelets.
In order to confirm these findings, the same type of experiment was performed with platelets from PN-1 -/-or PAI-1 -/-and their littermate controls. As observed above with human platelets, incubation of purified thrombin with the secretion products of activated platelets from WT mice resulted in a very significant inhibition of thrombin activity ( Figure 3C ). A similar result was obtained with activated platelets from PAI-1 -/-mice. On the contrary, the products secreted by platelets from PN-1 -/-mice did not inhibit thrombin activity ( Figure 3C ).
These results are in good agreement with those obtained with the anti-PN-1 antibody in human platelets. Together, they indicate that PN-1 secreted by activated platelets has an efficient inhibitory effect toward thrombin whereas PAI-1 is devoid of such an effect.
Because thrombin inhibition by PN-1 is known to be potentiated by GAGs, we investigated whether PN-1, secreted by activated platelets, was associated to GAGs. Secretion products of human platelets activated by PAR1-AP were incubated with or without polybrene, a polycation that neutralizes GAG-dependent interactions. Residual thrombin activity observed after activation (11%) was partially restored in the presence of polybrene (64%) ( Figure 3D ). This result indicated that PN-1 released from platelet α-granules was associated with GAGs. On the other hand, thrombin inhibition with the secretion products of activated platelets was accelerated in the presence of heparin (not shown), indicating that a fraction of PN-1 released by platelets is free.
Platelet PN-1 inhibits urokinase
We then tested whether PN-1 secreted by activated platelets inhibits uPA activity. No inhibition of uPA was observed in the presence of supernatant from resting human platelets ( Figure 4A ). In contrast, the products secreted by activated platelets significantly inhibited uPA, the residual activity dropping to 25.0 ± 7.9 % of the initial activity ( Figure To substantiate these results, experiments were performed using mouse platelets. The activity of uPA was inhibited in the presence of the products secreted by activated WT platelets ( Figure 4C ), in agreement with the data obtained with human platelets. In contrast, the secretion products from activated PN-1-deficient platelets did not inhibit uPA, the residual activity remaining at 91.0 ± 6.5 %. The products secreted by activated PAI-1-deficient platelets partially inhibited uPA ( Figure 4C ).
Taken together, our findings indicate that both PN-1 and PAI-1 released by activated platelets contribute to inhibit uPA.
Platelet PN-1 delays time to peak and reduces the peak of thrombin generated by tissue factor (TF) in platelet-rich-plasma (PRP)
The respective role of PN-1 and PAI-1 in the production of thrombin induced by TF in human and mouse PRP were investigated using the thrombogram method. The thrombin generation curve (thrombogram) is characterized by several parameters: 1) the lag phase related to the clotting time, 2) the peak height which represents the maximal net thrombin production and reflects the maximum prothrombinase activity reached, 3) the time to peak which reflects the velocity, and 4) the endogenous thrombin potential (ETP), namely the area under the curve representing the total amount of active thrombin generated during the assay.
The effects of the anti-PN-1 and anti-PAI-1 antibodies on thrombin generation in human PRP are shown in Figures 5A-B and quantitative parameters are reported in Table 1 . The anti-PN-1 antibody significantly shortened the thrombin burst as indicated by the reduced time to peak and significantly increased the peak height, but did not modify the ETP ( Figure 5A and Table   1 ). The anti-PAI-1 antibody and the irrelevant antibody had no significant effect on the thrombin generation parameters ( Figure 5B and Table 1 ). Neither the anti-PN-1 nor the anti-PAI-1 antibodies affected TF-induced thrombin generation in platelet-poor-plasma (PPP) (not shown), confirming that PN-1 originated from platelets.
Thrombinography was also performed on mouse PRP. TF-triggered thrombin generation was accelerated (shorter lag time and time to peak) and the peak height was significantly increased in the PRP from PN-1 -/-mice ( Figure 5C and Table 2 ). No significant differences were observed in the thrombogram parameters obtained with PRP from PAI-1 -/-and WT mice ( Figure 5D and Table 2 ). As observed with human PPP, no significant differences in the thrombogram parameters were observed between WT, PN-1-and PAI-1-deficient PPP (data not shown). Taken together, these results show for the first time that platelet PN-1, but not PAI-1, regulates TF-induced thrombin generation in PRP.
Platelet PN-1 decreases mouse platelet activation and aggregation and reduces collageninduced thrombus formation under blood flow conditions
We investigated whether platelet PN-1 could regulate thrombin-induced platelet activation and aggregation. For this purpose, platelets from WT and PN-1 -/-mice, activated by increasing concentrations of thrombin, were monitored for surface exposure of P-selectin using flow cytometry. The dose response curve was displaced to the left for PN-1-deficient and 51 ± 3% respectively ( Figure 6E ). In the presence of the thrombin inhibitor PPACK no differences were observed between both types of platelets ( Figure 6E ). These results For
Discussion
Experimental evidence have previously suggested that platelets store and secrete PN- 6 , 7 who detected PN-1 at the platelet surface only after activation, we provide direct evidence that PN-1 is present at the surface of resting platelets but it represents a minor fraction of total PN-1 compared to the cytosol fraction. The apparent discrepancy between these results can be explained by the improvement of the methods which allow to detect low levels of PN-1. We have previously reported that PN-1 is associated with membrane GAGs and proteoglycans on vascular cells from where it can be displaced by heparin. 31 PN-1 bound to the platelet surface is also displaced by heparin. Since membrane-bound PN-1 is undetectable on Gray platelets, PN-1 is probably translocated to the membrane during platelet production. Surface exposure of PN-1 is unlikely the consequence of platelet activation since platelets were P-selectin negative and activating platelets in vitro did not result in an increased, but in contrast, in a decreased binding of the FITC-coupled anti-PN-1 antibody, indicating a shedding of membrane PN-1 upon platelet activation.
Storage of PN-1 in α-granules allows its secretion in significant amounts. Our data show undoubtedly that platelet PN-1 is secreted in an active form during platelet activation since it very efficiently inhibits thrombin. As indicated by the experiments with polybrene, platelet PN-1 is secreted, at least in part, in association with heparin-like GAGs, which have been shown to enhance its interaction with thrombin.
The inhibitory activity of PN-1, secreted during platelet activation, on both thrombin and uPA was evidenced on both human and mouse platelets using respectively a specific PN-1-blocking antibody and platelets from PN-1-deficient animals. These data suggest that platelet PN-1 is a potential player in the control of fibrinolysis. PAI-1 is also stored in α-granules 3 and de novo synthesis of PAI-1 has been reported to occur in human platelets. 35 In humans, platelet PAI-1 released locally after activation is assumed to be a major contributor to the stabilization of the thrombus by inhibiting endogenous fibrinolysis, 2, 36 but PAI-1-independent mechanisms have also been proposed to contribute to platelet-dependent inhibition of fibrinolysis. 5 In the present study no role for secreted PAI-1 in inhibiting uPA was observed with mouse platelets. This is in agreement with a previous report demonstrating significant differences between human and mice fibrinolytic systems. For 
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